What is Psychemedics?
Founded in 1986, Psychemedics has carved out a specialized niche as a premier provider of patented hair testing technology for drug detection. By offering a sophisticated alternative to traditional urinalysis, the company serves a diverse clientele ranging from high-stakes financial institutions to law enforcement agencies and educational organizations. Its business model centers on the intersection of rigorous research and development and high-volume screening services, positioning the firm as a critical partner for entities requiring reliable, non-invasive, and long-window substance abuse monitoring. The company's ability to maintain a competitive edge in the diagnostic industry is rooted in its commitment to scientific precision and its expansive, multi-location operational footprint across the United States.
How much funding has Psychemedics raised?
Psychemedics has raised a total of $2M across 1 funding round:
Debt
$2M
Debt (2020): $2M with participation from PPP
Key Investors in Psychemedics
PPP
Public-Private Partnership
What's next for Psychemedics?
Looking ahead, the infusion of capital is expected to accelerate the company's strategic initiatives in the diagnostic technology space. As the demand for more accurate and tamper-resistant drug screening methods grows, Psychemedics is well-positioned to scale its B2B and B2C service offerings. The current funding context suggests a focus on enhancing laboratory throughput and expanding the reach of its patented testing processes. By leveraging this financial support, the organization aims to reinforce its market dominance, potentially exploring new technological integrations that align with evolving regulatory standards and the increasing corporate emphasis on workplace safety and compliance. The firm's trajectory remains focused on long-term value creation through technological innovation and market penetration.
See full Psychemedics company page
